Augmentation of Atrophic Mandibule Using Poly Ether Ether Ketone Mesh (RCT)

July 18, 2022 updated by: Adham Zakaria, Cairo University

Comparative Study Between Custom-made Polyether Ether Ketone and Titanium Mesh for Augmentation of Atrophic Posterior Mandible. Randomized Clinical Trial

Comparative study between custom-made polyether ether ketone and titanium mesh for augmentation of atrophic posterior mandible.

Study Overview

Detailed Description

Designing and manufacturing

1. The CBCT images of the patient will be used to build a digital model using a 3D planning software (Mimics innovation suite). Based on this model, a machine will be used to mill a pressed and pre-sintered body of PEEK to the desired macroscopic shape.

2. The size of the machined sheet is enlarged in order to compensate for the sintering shrinkage performed at 1450 C.

3. After manufacturing, the sheet will be cleaned in an ultrasonic bath of 70% alcohol for 15 min, followed by a brief heating to 1200 C.

4. It will be again cleaned in an ultrasonic bath for 3x15 min using 90% alcohol.

5. Thereafter the sheet was placed in an autoclave and sterilized using a standard program.

6. The sheets will have a thickness of approximately 0.5 - 0.7 mm. b. Surgery

  1. The intraoral area is initially cleaned with chlorhexidine 1 mg/ml.
  2. Local anesthesia is administered.
  3. Horizontal crestal incisions are made lingual of the mid-crest within the keratinized tissue. Vertical releasing incisions are placed on the buccal aspect of the surgical site in the usual manner to provide adequate access and to allow for eventual coronal repositioning.
  4. Then, a full-thickness mucoperiosteal flap is reflected to completely expose the atrophic ridge.
  5. The cortex of the mandibular crest is generously perforated to produce bleeding in multiple sites. The pilot holes for the fixation screws were also prepared at this time.
  6. The barrier is inserted over the mandible and compressed into place, the fixation screws are inserted and no adaptation will be needed as the barrier is custom-made for the edentulous ridge.
  7. The ceramic sheets is cleaned with 3% hydrogen peroxide prior to soft tissue closure.
  8. After fixation of the sheets, the buccal flaps should be coronally repositioned.
  9. Split-thickness periosteal releasing incisions are completed to aid in primary tension-free closure. The flap margins are then advanced over the barrier and approximated to evaluate for tension-free closure.
  10. After a mean of 6 months of uneventful healing, the augmented sites are reopened. The ceramic barrier and fixation screws are identified and removed, followed by Dental implant.

Post-operative care:

Avoid traumatization of the surgical site. Patients must abstain from brushing at the surgical area. Instead, a disinfecting mouth rinse should be used (e.g. chlorhexidine 0.2%).

Instruct the patient not to touch or manipulate the surgical area. Ice packs for 10 minutes every 30 minutes for 24 hours. Do not use removable dentures during the expansion phase. Temporary fixed partial dentures must be adjusted to the expected tissue gain.

No consume of tobacco

Post-operative medications will be prescribed as follows:

Amoxicillin/clavulanic acid tablets 10mg/kg every 12 hours for 7 days, diclofenac potassium 50mg every 8 hours for 4 days and then as needed, metronidazole 5 mg/kg every 8 hours for 7 days and chlorhexidine gluconate 0.1% mouthwash 3 times daily for 14 days.

11b. Criteria for discontinuing or modifying intervention: No protocol for discontinuation of the procedure. 11c. Strategies to improve adherence to intervention: Face to face adherence reminder session will take place to stress on the post-operative instructions at the following time intervals.

Patients were recalled every other day to monitor soft tissue healing for the first week, one visit weekly for the first month then monthly for 6 months.

Study Type

Interventional

Enrollment (Anticipated)

14

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

  • Name: Adham Y Zakaria, Master
  • Phone Number: 00201226000741

Study Locations

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

20 years to 50 years (Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  1. Patients with atrophic posterior mandible
  2. Both sexes
  3. No intraoral soft and hard tissue pathology
  4. No systemic condition that contraindicate implant placement

Exclusion Criteria:

  1. Untreated gingivitis, periodontitis
  2. Insufficient oral hygiene
  3. Previous radiation therapy the head and neck neoplasia, or bone augmentation to implant site.
  4. Systemic disorders
  5. Heavy smoking more than 20 cigarettes per day
  6. Bone pathology
  7. Psychiatric problems
  8. Emotional instability
  9. Unrealistic aesthetic demands

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Custom Made Poly Ether Ether Ketone Mesh
Applying Poly Ether Ether Ketone mesh with mix of autogenous bone graft and bone substitute in posterior atrophic mandible for augmentation
comparing between PEEK mesh and Titanium mesh for augmentation of posterior atrophic mandible using mix of autogenous bone graft and bone substitute.
Active Comparator: Conventional Titanium mesh
Applying Titanium mesh with mix of autogenous bone graft and bone substitute in posterior atrophic mandible for augmentation
comparing between PEEK mesh and Titanium mesh for augmentation of posterior atrophic mandible using mix of autogenous bone graft and bone substitute.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Vertical amount of bone increased (length in millimeters). horizontal amount f bone increased after augmentation (width in millimeters).
Time Frame: 6 months
Length (Vertical Augmentation) Width (horizontal augmentation) gained after augmentation of atrophic mandible in millimeters using cone beam computed tomography (measuring tool) measurment tools : with the aid of cone beam computed tomography
6 months

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Rate of Soft Tissue Dehiscence
Time Frame: 6 months
which mesh will cause soft tissue dehiscence more.
6 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Study Director: Mohamed F Shehab, PHD, Professor of Oral and Maxillofacial Surgery - Cairo University.
  • Study Director: Khaled A Salaheddin, PHD, Lecturer of Oral and Maxillofacial Surgery - Cairo University.

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

June 25, 2019

Primary Completion (Anticipated)

November 25, 2022

Study Completion (Anticipated)

December 1, 2022

Study Registration Dates

First Submitted

June 25, 2019

First Submitted That Met QC Criteria

July 10, 2019

First Posted (Actual)

July 12, 2019

Study Record Updates

Last Update Posted (Actual)

July 20, 2022

Last Update Submitted That Met QC Criteria

July 18, 2022

Last Verified

July 1, 2022

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

No

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Mandible Small

3
Subscribe